Key Highlights

  • On November 19, two days after a proposed USD 150.0 million public offering followed Phase 3 REGAL survival results, SELLAS Life Sciences (NASDAQ:SLS) shares traded 13.98% lower at USD 15.44.
  • PepGen (NASDAQ:PEPG) gained 8.82% to USD 4.16 but remains about 16.8% below the USD 5.00 offering price (calculated), with no dated news for the day; that raise was aimed at USD 125 million.
  • ARS Pharmaceuticals (NASDAQ:SPRY) fell 7.62% to USD 3.41 and no announcement was located; the most recent figures, third-quarter sales of USD 37.7 million with a smaller loss, came earlier.
  • Evolent Health (NYSE:EVH) slipped 5.47% to USD 3.71 with no announcement located, after its medical expense ratio rose to 93.0% from 85.0% a year earlier.

SELLAS Life Sciences (NASDAQ:SLS): Share Sale Follows a Phase 3 Win

On Thursday, November 19, 2026, intraday figures had SELLAS Life Sciences (NASDAQ:SLS) at USD 15.44, a 13.98% decline that points to a prior close of about USD 17.95 (calculated). It is the only company in the group with a clearly announced trigger. Galinpepimut-S, examined in acute myeloid leukemia within the Phase 3 REGAL study, reached its primary overall survival goal, the company said on November 17, 2026. Treated patients had a median survival of 24.0 months compared with 14.7 months under best available therapy, a hazard ratio of 0.59 and a p-value of 0.035. A proposed underwritten raise of USD 150.0 million followed, with underwriters holding a 30-day right to up to USD 22.5 million more shares; J.P. Morgan and TD Cowen run the books. Because the company alone is selling, fresh shares enlarge the base and dilute those already holding stock. Pricing per share had not been disclosed and final terms were unconfirmed, leaving the discount unknown. Cash was USD 134.7 million on September 30, 2026, and 203,527,833 shares were outstanding. Risks include an open-label design with 126 patients, a p-value sitting only slightly below 0.05, and a regulator that could seek additional data. A Biologics License Application is in preparation for the first half of 2027, and thinly traded stocks can swing on few transactions.

PepGen (NASDAQ:PEPG): Recovery Stalls Below the Offering Price

Intraday trading had PepGen (NASDAQ:PEPG) up 8.82% at USD 4.16, although the stock stands roughly 16.8% beneath the recent USD 5.00 offering level (simple arithmetic on two published numbers). Searches found no company announcement for November 17 to 19, so this bounce lacks a fresh trigger. Pricing took place on November 11, 2026: 25 million shares at USD 5.00 apiece were expected to bring in USD 125 million gross, with underwriters able to acquire 3.75 million additional shares within a month. Settlement and any exercise of that option remain unverified. The raise followed Phase 2 data on PGN-EDODM1, a candidate aimed at myotonic dystrophy type 1; at 10 mg/kg the average splicing correction was 46.5%; five of six participants passed 20% and four passed 50%. Cash totalled USD 104.8 million on September 30, 2026; adding the gross raise before fees gives about USD 229.8 million (calculated). Losses for the third quarter totalled USD 19.4 million. The chief hazard is the partial clinical hold from the FDA, imposed in March 2026, which blocks the path to a regulatory meeting slated for the second half of 2027; dilution and the Volatility typical of cheap shares add to that.

ARS Pharmaceuticals (NASDAQ:SPRY): Decline With No Explanation Offered

Intraday figures placed ARS Pharmaceuticals (NASDAQ:SPRY) at USD 3.41 on November 19, 2026, a 7.62% retreat from an implied prior close near USD 3.69 (calculated). Research turned up no company statement, filing or analyst move for November 17 to 19, so no catalyst can be named. The newest concrete news is the third-quarter release dated November 5, 2026: sales reached USD 37.7 million, up from USD 32.5 million, while U.S. net product sales of neffy, a needle-free epinephrine nasal spray, came to USD 33.4 million against USD 31.3 million, about 6.7% growth (calculated). The net loss contracted to USD 35.6 million, or USD 0.36 a share, partly because selling expenses fell to USD 43.5 million from USD 74.8 million. Management explained that end-user purchasing outran reported sales owing to shifts in channel inventory. Cash and short-term investments stood at USD 138.4 million, down from roughly USD 245.0 million at December 31, 2025, a drop of about USD 107 million (calculated). The company aims to reach cash-flow breakeven by the end of 2027, so funding becomes the specific hazard if that timetable slips. Published coverage pointed to term-loan Debt of about USD 121.8 million, a figure not verified here.

Evolent Health (NYSE:EVH): Top-Line Growth Alongside a Heavier Medical Expense Ratio

Evolent Health (NYSE:EVH) dipped to USD 3.71, a 5.47% decline, in intraday trading on November 19, 2026. As with the earlier name, no announcement linked to the move appeared, and the latest confirmed item is the third-quarter release dated November 5, 2026. Growth and tighter profitability showed up together in that report: Revenue jumped to USD 725.4 million from USD 479.5 million, though adjusted EBITDA eased to USD 34.3 million, down from USD 39.0 million. The medical expense ratio, which captures how much of revenue flows into care costs under risk-based agreements, rose to 93.0% from 85.0%, pulling the adjusted EBITDA Margin down to 4.7% from 8.1%. Management raised its 2026 adjusted EBITDA outlook to USD 130.0 million to USD 135.0 million, while holding the revenue outlook in a USD 2.6 billion to USD 2.7 billion band. Leverage is the chief concern: cash of USD 148.3 million sits against net long-term debt of USD 969.5 million, which is about USD 821.2 million after netting cash (calculated). Up to USD 50 million is slated to go toward debt reduction by year-end, and new contracts need time before they lift margins.

Where Things Stand

SELLAS Life Sciences (NASDAQ:SLS) is the one name here with a clear trigger: its USD 150.0 million raise, launched after Phase 3 data, goes with the 13.98% decline. The other three moves share a sector but lack a common cause. PepGen (NASDAQ:PEPG) gained 8.82% yet still trades under its USD 5.00 offering price, with no news located for the day. ARS Pharmaceuticals (NASDAQ:SPRY) dropped 7.62% with no announcement located. Evolent Health (NYSE:EVH) gave up 5.47% on the same footing, so neither decline can be pinned on one event. The thread running through all four is financing: dilution at SELLAS and PepGen, cash consumption at ARS and debt at Evolent. Upcoming checkpoints include SELLAS pricing details and its FDA meeting, PepGen's clinical hold and January 2027 data, ARS-2's first-quarter 2027 readout and Evolent's debt paydown by year-end. Nothing here promises the way these shares will trade.